Imaging-based markers of treatment response are increasingly being used in studies of brain-tumour therapies, for evaluating novel treatments and further understanding of existing therapies. An ultimate goal of these studies is to identify pre-or early-stage treatment imaging biomarkers that enable prediction of subsequent treatment response. We hypothesised that pretreatment MRI-based measurements of tumoural perfusion may provide a suitable imaging-based biomarker for prediction of subsequent treatment response and evaluated this in a group of nine high-grade glioma patients undergoing dexamethasone treatment. A strong positive correlation was observed between tumoural blood flow (R 2 ¼0.90, p<0.001) and tumoural blood volume (R 2 ¼0.76, p¼0.002), and subsequent treatment response as measured by alterations in tumour leakage properties. These preliminary results indicate that measurements of tumoural perfusion may provide useful imaging biomarkers for predicting treatment response to dexamethasone and would therefore also be worth evaluating in newer emerging therapies.
INTRODUCTION
Dexamethasone has been used for the management of intracranial tumours since early clinical observations of its efficacy in these patients. 1 However, despite a generally accepted rapid and beneficial clinical effect, there is still a significant amount of variability in the degree of response between patients. 2 This is, perhaps, unsurprising given the highly variable and heterogeneous nature of the tumour microenvironment and vascular properties. Imaging techniques offer a mechanism for noninvasively characterising the tumour microenvironment, potentially leading to identification of imaging biomarkers for characterising and predicting treatment response.
MRI techniques have been developed to enable measurement of parameters such as diffusion, perfusion, permeability, pH, and water content. These parameters provide useful information about the tumour microenvironment and have been studied extensively in intracranial tumours as potential markers of treatment response. 7e12 However, to date, no study has been performed to identify if these biomarkers, when measured pretreatment, can be used to predict subsequent response. As a first step towards this, we investigated whether MRI-derived biomarkers, measured pretreatment, correlate with subsequent response to treatment at 48e72 h following initiation. In particular, we hypothesised that tumoural perfusion could be a useful biomarker for predicting treatment response due to dexamethasone, since tumoural blood supply may influence dexamethasone distribution into tumoural tissue. To investigate this, MRI measurements of perfusion, permeability and diffusion were performed in a group of high-grade glioma patients before and 48e72 h following initiation of dexamethasone therapy. Pretreatment perfusion values were correlated with subsequent image-based responses to treatment.
MATERIALS AND METHODS Patients
Nine consecutive patients with radiologically diagnosed WHO Grade IV glioblastoma multiforme (later confirmed by histology) were recruited into the study (mean age 6369 years, five females). Patients were recruited if they had (1) no MR contraindications, (2) not begun steroid treatment and (3) no prior radiotherapy or chemotherapy. Following initial imaging, patients underwent dexamethasone therapy (16 mg/day PO) before undergoing follow-up imaging 48e72 h later. The local ethics committee approved the study, and written informed consent was obtained from all patients.
Imaging measurements
All imaging was performed on a GE Signa LX 1.5T scanner (General Electric, Milwaukee, Wisconsin) and consisted of clinical imaging, dynamic susceptibility contrast MRI (DSC-MRI), dynamic contrast-enhanced MRI (DCE-MRI) and diffusion tensor MRI (DT-MRI). Each of the DCE-and DSC-MRI protocols was performed using separate 20 ml injections of gadopentetate dimeglumine (Magnevist, Berlex Laboratories, Wayne, New Jersey) into the anticubital fossa vein at 5 ml/s using an MRcompatible power injector (Medrad, Indianola, Pennsylvania). Full details of the MRI protocol have been described elsewhere.
11
Standard postprocessing techniques involving gamma-variate curve fitting were applied to the DSC-MRI data to obtain maps of relative perfusion parameters. 4 The regional cerebral blood volume (rCBV) was calculated from the area under the concentrationetime curve, the regional mean transit time (rMTT) from the first moment of the curve and the regional cerebral blood flow (rCBF) from the ratio of the first two. Concentrationetime curves were estimated from the DCE-MRI acquisition using a previously described model 13 and maps of the area under the concentrationetime curve (CA), volume transfer constant (K trans ), and extravascular extracellular space volume fraction (v e ) were obtained by fitting a pharmacokinetic model to the concentrationetime curves. 5 From a biological perspective, CA indicates the total amount of contrast agent accumulating during the course of the imaging period in each voxel, and K trans is a proxy for the endothelial permeability (actually the permeability e surface area product per unit volume of tissue). The DT-MRI data were used to calculate the mean diffusivity (D av ) as the average of the diagonal elements of the diffusion tensor. 3 This parameter measures the mobility of water and therefore indicates how free or restricted the local water environment is. Region-of-interest measurements were taken of rCBV, rCBF, rMTT, CA, K trans and v e in enhancing tumour (identified on postcontrast T 1 -weighted imaging) and D av in oedema, both pre-and post-treatment, using the methodology described previously. 11 Measurements of tumoural rCBV, rCBF and rMTT were divided by corresponding measurements from contralateral normal-appearing white matter to give CBV t , MTT t and CBF t , respectively. Therefore, for example, CBV t represents the proportion by which the tumoural rCBV is elevated above that of normal-appearing white matter, such that a CBV t of 2 would indicate that tumoural blood volume is twice that of normal-appearing white matter. Pretreatment measurements of CBV t , CBF t and MTT t were correlated with the percentage pre-to post-treatment reduction in tumour CA, Figure 1 illustrates typical examples from four subjects, illustrating how initial rCBF appearance compares with CA preand post-treatment, along with graphs illustrating the correlations between these parameters for all nine patients. Figure 1 Example graphs illustrating the correlation between DCA and CBF t for all nine patients (upper left) and DCA and CBV t (lower left). Also shown are images illustrating the striking visual correlation between pretreatment regional cerebral blood volume (rCBV) and pre-/post-treatment change in CA from four typical example cases with a range of different treatment responses (right).Delta CA is the percentage pre-to post-treatment reduction in CA where CA is the area under the concentration-time curve of the DCE-MRI analysis. CBFt is the pre-treatment regional cerebral blood flow (rCBF) value measured in tumoural tissue and normalised to its equivalent normal appearing white matter value. CBVt is the pre-treatment regional cerebral blood volume (rCBV) value measured in tumoural tissue and normalised to its equivalent normal appearing white matter value.
DISCUSSION
In addition to the expected reduction in tumour DCA, DK trans , Dv e and oedema DD av following dexamethasone therapy as identified in previous work, the results demonstrate a strong correlation between pretreatment CBV t and CBF t , and subsequent treatment response, as measured by DCA and Dv e . 7e12 This suggests that the supply of blood to the tumour is an important factor in determining response to dexamethasone, where the rate of blood supply CBF t appears to be the critical factor in determining dexamethasone response. While this correlation may be expected for a drug like dexamethasone, we believe this to be the first time this has been measured and demonstrated in a quantitative way.
Despite pretreatment tumoural perfusion being strongly correlated with DCA and Dv e , it does not correlate with DK trans , although this is known to be reduced post-treatment. 8 9 11 As CA is a function of both K trans and v e (as both of these parameters determine the area under the concentrationetime curve), the results indicate that the correlation between pretreatment perfusion and DCA arises from the correlation with Dv e . This suggests that dexamethasone may act to reduce the extravascular extracellular space, as well as a consequence of reducing tumour permeability. A further possibility is that the measurement of K trans may be prone to error with the current acquisition, due to the relatively long 55 s temporal resolution of the DCE-MRI acquisition.
14 It is encouraging that a strong correlation is observed using relatively simple measurements of area under the concentrationetime curve, in the case of CBV t for initial perfusion estimation from DSC-MRI and DCA for treatment response from DCE-MRI. Therefore, the methodology could easily be implemented in future studies, without the need for complex pharmacokinetic modelling. More rigorous modelling may be useful to aid understanding of treatment mechanisms and provide greater specificity.
The correlations observed between pretreatment CBV t and CBF t , and response measured by DD av did not reach statistical significance in the present study. This may reach significance with increased patient numbers, particularly given that significant correlations were observed between both DCA and DD av (R 2 ¼0.49, p¼0.03) and Dv e and DD av (R 2 ¼0.47, p¼0.04). The change in water diffusivity DD av was the only biomarker to be assessed in the oedematous brain tissue and therefore outwith the enhancing tumour region. Oedema resolution is believed to be one of the primary reasons for the beneficial clinical effects of dexamethasone, and so DD av could be considered more relevant to clinical outcome. 10 However, before any definitive conclusion could be drawn, a more detailed study would be required to correlate imaging-based measurements of oedema resolution with clinical responses.
The use of imaging biomarkers as surrogates for therapeutic responses, without direct measurement of clinical response, is a definite weakness of the present study. However, clinical response is difficult to quantify in brain-tumour patients, and would introduce other uncertainties and therefore require a larger patient study. 15 Nevertheless, correlation of pretreatment perfusion metrics with quantitative measures of neurological improvement would certainly be a worthwhile aim of future studies. The present study investigated the response at 48e72 h following treatment initiation, a period that is highly relevant in our centre, as this measures the response immediately prior to surgery. However, future studies could also look at responses over shorter or longer periods, although the interpretation of these results may be complicated once surgery has been performed. Another concern when using imaging-based markers of therapeutic response is that the response may merely be correlated with, or reflect, pretreatment values. For example, a high pretreatment tumoural rCBV may be indicative of there being more abnormal vasculature, and so a greater treatment effect may be expected, or vice versa. However, in this study, no significant correlations were observed between the initial pretreatment K trans , v e or CA and their respective post-treatment changes, or between initial CBF t and CBV t and their respective post-treatment change.
In conclusion, a strong correlation has been found between pretreatment MRI measurements of tumour perfusion and subsequent assessment of dexamethasone response. Larger studies are clearly required to validate these findings and their relevance to clinical function. These preliminary results suggest that pretreatment perfusion measurements would be worth while investigating as potential biomarkers of treatment response with newer therapies.
